Danshensu

Catalog No.S4741 Synonyms: Salvianic acid A

For research use only.

Danshensu (Salvianic acid A), a herbal preparation used in traditional Chinese medicine, possesses potential antitumor and anti‑angiogenesis effects. Danshensu inhibits CYP2E1 and CYP2C9 with IC50 of 36.63 and 75.76 μm, respectively.

Danshensu Chemical Structure

CAS No. 76822-21-4

Purity & Quality Control

Choose Selective P450 (e.g. CYP17) Inhibitors

Other P450 (e.g. CYP17) Products

Biological Activity

Description Danshensu (Salvianic acid A), a herbal preparation used in traditional Chinese medicine, possesses potential antitumor and anti‑angiogenesis effects. Danshensu inhibits CYP2E1 and CYP2C9 with IC50 of 36.63 and 75.76 μm, respectively.
Targets
CYP2E1 [3]
(Cell-free assay)
CYP2C9 [3]
(Cell-free assay)
36.63 μM 75.76 μM
In vitro

Danshensu reduces lipid peroxidation on mitochondrial membrane by scavenging free radicals, and inhibits permeability and transmission of mitochondrial membrane by reducing thiol oxidation[1]. Danshensu markedly improves cell viability and decreased lactate dehydrogenase (LDH) release in H9c2 cardiomyocytes. Danshensu increases phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu are partially inhibited by phosphatidylinositol 3'-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126. Danshensu could provide significant cardioprotection against MI/R injury, and the potential mechanisms might to suppression of cardiomyocytes apoptosis through activating the PI3K/Akt and ERK1/2 signaling pathways. Danshensu increases Bcl-2 expression and decreases Bax, active caspase-3 expression by activating Akt and ERK signaling pathways. Danshensu has been demonstrated to have biological activities in improving microcirculation, suppressing the formation of reactive oxygen species, inhibiting platelet adhesion and aggregation, protecting myocardium against ischemia, protecting endothelial cells against injury induced by inflammation[2].

In vivo

Pretreatment with danshensu in ISO-administered rats shows a significant (P<0.001) decrease in ST-segment as compared to ISO-administered rats. Its pretreatment also shows significant (P<0.001) decrease in the levels of serum cTnI when compared to the ISO. Thus, danshensu exerts significant cardioprotective effects against ISO-induced myocardial infarction in rats[1]. In the rat model of MI/R injury, Danshensu significantly reduces myocardium infarct size and the production of creatine kinase-MB (CK-MB), cardiac troponin (cTnI) in serum[2].

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: Rat H9c2 cardiomyocyte cell line
  • Concentrations: 1 μM or 10 μM
  • Incubation Time: --
  • Method:

    Cardiomyocytes are exposed to ischemia by replacing medium with an 'ischemic buffer', this buffer is designed to simulate the extracellular milieu of myocardial ischemia, with the approximate concentrations of potassium, hydrogen, and lactate ions occurring in vivo. Cells are incubated in the hypoxic/ischemic chamber at 37℃ for 2 h in a humidified atmosphere of 5% CO2 and 95% nitrogen. At the onset of reperfusion, cardiomyocytes are randomly exposed to one of the following treatments: vehicle, Danshensu (1 μM or 10 μM), Danshensu plus the PI3K inhibitor wortmannin (10 nM), Danshensu plus the ERK inhibitor U0126 (10 μM). Simultaneously, in the control group, H9c2 cardiomyocytes are cultured under normal conditions in CO2 incubation.

Animal Research:

[1]

  • Animal Models: Sprague-Dawley rats
  • Dosages: 160 mg/kg
  • Administration: oral administration

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 198.17
Formula

C9H10O5

CAS No. 76822-21-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C=C1CC(C(=O)O)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Danshensu | Danshensu supplier | purchase Danshensu | Danshensu cost | Danshensu manufacturer | order Danshensu | Danshensu distributor